Sebaldt RJ, Sheller JR, Oates JA, et al Inhibition of eicosanoid
biosynthesis by glucocorticoid in humans.
Maintenance of lower proportions of (n - 6) eicosanoid
precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids.
Oral green tea catechin metabolites are incorporated into human skin and protect against UV radiation-induced cutaneous inflammation in association with reduced production of pro-inflammatory eicosanoid
For quantitative catecholamine and eicosanoid
determination, the limit of detection or quantification was determined from the daily calibration curve, and absolute quantification was performed with stable isotope-labeled standards.
Omega-3 fatty acids regulate the production of eicosanoid
in the human body.
These mechanisms of n-3 PUFA regulate inflammation via the eicosanoid
The reduction of eicosanoid
release was related to the inhibition of cyclooxygenase-2 expression.
The regulation of eicosanoid
production occurs, in part, via the coordinated spatial-temporal expression of associated enzymatic pathways that vary according to cell type and upon the state of cellular activation.
Omega-3 and some omega-6 (eg GLA) FFAs generate anti-inflammatory mediators via the eicosanoid
Ongoing investigations of eicosanoid
metabolites in the laboratory have led to the discovery of novel therapeutic targets for cardiovascular diseases.
Prostaglandins and leukotrienes: Advances in eicosanoid
Prostacyclin opposes the effects of thromboxane, a thrombogenic and atherogenic eicosanoid